Get started
BIOCRYST PHARMACEUTICALS INCBIOCRYST PHARMACEUTICALS INCBIOCRYST PHARMACEUTICALS INC

BIOCRYST PHARMACEUTICALS INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

BCRX trade ideas

Bullish Charts - Above the Cloud, Ready to Spike, Zika VirusBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Daily Chart: Volume: Bullish PMO Turning Up, Bullish MACD Turning Up, Bullish RSI: Bullish Stochastic: Bullish OBV: Bullish Accumulation: Bullish Sector: Bullish Closed above the cloud on Friday - Bullish On 06/10/2020, Company reported Galidesivir stopped the Zika virus replication. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:BCRXLong
by HotCharts
BCRX 1 year base breakout, Desc. TriangleDaily chart: BCRX has broken out of a 1 year long base, turning the $4.00 level resistance into strong support. Price currently consolidating in a descending triangle using the $4.00 level and the 50 day EMA as support. 1HR: BCRX has not closed below $4.14 in last month while the breakout level has been tested at minimum 5 times (depending on what you count as a test), each time producing a wick only as low as $4.08. A stop loss of just sub $4 or even $4.05 could give you a low risk trade opportunity. BCRX must clear $4.40 to get above the hourly EMAs, so I also like the idea of waiting for that to occur and then using a stop of $4.25. Either way, if you are nimble you I believe it's realistic to enter a trade here with a downside risk of 5%. Near term, this is Covid related and is going to be bid up if the Covid narrative becomes prominent in the market again. See my link at the bottom regarding $VIR and $BNTX that show a similar consolidation pattern over the last month, not participating in the broader market rally and now starting to look technically bullish. I like BCRX from a technical standpoint, risk standpoint and I believe it's bull case is bolstered by recent strength in other Covid stocks. www.biopharmcatalyst.com finviz.com Covid related drug name with several programs and some good press recently. (That's as much fundamental work as I do). Link above will give you pipeline and press releases. Per Finviz, $7 target given 5/5/20.
NASDAQ:BCRXLong
by ETrades1
COVID-19 TREATMENTA company that designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. anticipates two regulatory approvals for berotralstat in 2020, Even more impressive, that BCRX will likely get a significant near-term boost from the success of GILD's remdesivir in the treatment of COVID-19. it will help us a lot to conquer against the PANDEMIC. let the BULLS trend here!
NASDAQ:BCRXLong
by lyriccal12
Waiting to breakout..... or NOTStop loss $3.3 Buy at $4.4 if close above it If I can only lose $200 here, my share count should be $200/(4.4-3.3)=182 shares there may be chance to add more shares along the way Make sure your move your stop loss up if it will go up along the way. Remember: Your goal is not to calculate how much money you can make, but how much you can afford to lose. There always will be a opportunity in the future, only if you still have money to stay in the game.
NASDAQ:BCRX
by davidhaiyangzou
5